BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23562753)

  • 1. Intervention strategies for emerging viruses: use of antivirals.
    Debing Y; Jochmans D; Neyts J
    Curr Opin Virol; 2013 Apr; 3(2):217-24. PubMed ID: 23562753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of antivirals: broad-spectrum inhibitors.
    Debing Y; Neyts J; Delang L
    Curr Opin Infect Dis; 2015 Dec; 28(6):596-602. PubMed ID: 26524332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses.
    Wang X; Zou P; Wu F; Lu L; Jiang S
    Front Med; 2017 Dec; 11(4):449-461. PubMed ID: 29170916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivirals with common targets against highly pathogenic viruses.
    Lu L; Su S; Yang H; Jiang S
    Cell; 2021 Mar; 184(6):1604-1620. PubMed ID: 33740455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging viruses: risk of pandemic.
    Labonté P; Seidah NG
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):581-3. PubMed ID: 18847397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial overview: Engineering for viral resistance.
    von Brunn A
    Curr Opin Virol; 2015 Oct; 14():v-vii. PubMed ID: 26320757
    [No Abstract]   [Full Text] [Related]  

  • 7. New pathogenic viruses and novel antiviral drugs.
    Berkhout B; Eggink D
    Expert Rev Anti Infect Ther; 2011 Feb; 9(2):161-3. PubMed ID: 21342061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug combination therapy for emerging viral diseases.
    Shyr ZA; Cheng YS; Lo DC; Zheng W
    Drug Discov Today; 2021 Oct; 26(10):2367-2376. PubMed ID: 34023496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad-spectrum antivirals against viral fusion.
    Vigant F; Santos NC; Lee B
    Nat Rev Microbiol; 2015 Jul; 13(7):426-37. PubMed ID: 26075364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases.
    Guo D
    Virol Sin; 2020 Jun; 35(3):253-255. PubMed ID: 32048130
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday.
    Li G; Yue T; Zhang P; Gu W; Gao LJ; Tan L
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33572409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mining the tree of life: Host defense peptides as antiviral therapeutics.
    Shartouny JR; Jacob J
    Semin Cell Dev Biol; 2019 Apr; 88():147-155. PubMed ID: 29524585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibodies as candidate therapeutics against emerging viruses.
    Jin Y; Lei C; Hu D; Dimitrov DS; Ying T
    Front Med; 2017 Dec; 11(4):462-470. PubMed ID: 29159596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-spectrum Respiratory Virus Entry Inhibitors.
    Zhao H; Yuen KY
    Adv Exp Med Biol; 2022; 1366():137-153. PubMed ID: 35412139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of resveratrol against emerging respiratory viral infections.
    Filardo S; Di Pietro M; Mastromarino P; Sessa R
    Pharmacol Ther; 2020 Oct; 214():107613. PubMed ID: 32562826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human viral diseases: what is next for antiviral drug discovery?
    De Clercq E
    Curr Opin Virol; 2012 Oct; 2(5):572-9. PubMed ID: 22846888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.
    Pattabhi S; Wilkins CR; Dong R; Knoll ML; Posakony J; Kaiser S; Mire CE; Wang ML; Ireton RC; Geisbert TW; Bedard KM; Iadonato SP; Loo YM; Gale M
    J Virol; 2015 Dec; 90(5):2372-87. PubMed ID: 26676770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral treatment of severe non-influenza respiratory virus infection.
    Brendish NJ; Clark TW
    Curr Opin Infect Dis; 2017 Dec; 30(6):573-578. PubMed ID: 29095723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial overview: antivirals and resistance: advances and challenges ahead.
    Menéndez-Arias L; Richman DD
    Curr Opin Virol; 2014 Oct; 8():iv-vii. PubMed ID: 25155454
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomolecular Condensates as Novel Antiviral Targets.
    Martin EW; Iserman C; Olety B; Mitrea DM; Klein IA
    J Mol Biol; 2024 Feb; 436(4):168380. PubMed ID: 38061626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.